- seekingalpha.com
- Posted On 19 November 2026
Avalyn Pharma: The Tolerability Budget Is The Real Battleground In Pulmonary Fibrosis
Avalyn Pharma's ( AVLN ) approach has an aspect I do not feel has yet been adequately priced by the market. For most of the last decade, the pulmonary fibrosis ...
Source:
seekingalpha.com